Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Oxidized CaMKII promotes asthma through the activation of mast cells
Jingjing Qu, Danh C. Do, Yufeng Zhou, Elizabeth Luczak, Wayne Mitzner, Mark E. Anderson, Peisong Gao
Jingjing Qu, Danh C. Do, Yufeng Zhou, Elizabeth Luczak, Wayne Mitzner, Mark E. Anderson, Peisong Gao
View: Text | PDF
Research Article Immunology Pulmonology

Oxidized CaMKII promotes asthma through the activation of mast cells

  • Text
  • PDF
Abstract

Oxidation of calmodulin-dependent protein kinase II (ox-CaMKII) by ROS has been associated with asthma. However, the contribution of ox-CaMKII to the development of asthma remains to be fully characterized. Here, we tested the effect of ox-CaMKII on IgE-mediated mast cell activation in an allergen-induced mouse model of asthma using oxidant-resistant CaMKII MMVVδ knockin (MMVVδ) mice. Compared with WT mice, the allergen-challenged MMVVδ mice displayed less airway hyperresponsiveness (AHR) and inflammation. These MMVVδ mice exhibited reduced levels of ROS and diminished recruitment of mast cells to the lungs. OVA-activated bone marrow–derived mast cells (BMMCs) from MMVVδ mice showed a significant inhibition of ROS and ox-CaMKII expression. ROS generation was dependent on intracellular Ca2+ concentration in BMMCs. Importantly, OVA-activated MMVVδ BMMCs had suppressed degranulation, histamine release, leukotriene C4, and IL-13 expression. Adoptive transfer of WT, but not MMVVδ, BMMCs, reversed the alleviated AHR and inflammation in allergen-challenged MMVVδ mice. The CaMKII inhibitor KN-93 significantly suppressed IgE-mediated mast cell activation and asthma. These studies support a critical but previously unrecognized role of ox-CaMKII in mast cells that promotes asthma and suggest that therapies to reduce ox-CaMKII may be a novel approach for asthma.

Authors

Jingjing Qu, Danh C. Do, Yufeng Zhou, Elizabeth Luczak, Wayne Mitzner, Mark E. Anderson, Peisong Gao

×

Figure 5

ROS production is dependent on intracellular Ca2+.

Options: View larger image (or click on image) Download as PowerPoint
ROS production is dependent on intracellular Ca2+.
(A) Representative Fl...
(A) Representative Fluo-4 fluorescence heatmap images of anti-OVA IgE-sensitized BMMCs showing changes in [Ca2+]i induced by OVA. Representative of 3 independent experiments. Scale bar: 20 μm. (B) Representative mean fluorescent intensity (MFI) average traces for sensitized and challenged BMMCs from WT and MMVV BMMCs. CIB, Ca2+ imaging buffer. (C) Quantification of total calcium response from sensitized and challenged cells (>150 cells counted per condition) by calculating the AUC. (D and E) Levels of intracellular ROS in OVA-sensitized and challenged WT (D) or MMVVδ (E) BMMCs in the presence of IP3 receptor antagonist 2-APB by flow cytometry with CM-H2DCFDA. Data represent mean ± SEM, a single time point from 3 independent experiments. Comparisons were made using 2-tailed Student’s t test between OVA-treated WT vs. MMVV group (C) or 2-APB–treated vs. nontreated OVA-activated WT (D) and MMVVδ BMMCs (E). *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts